<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846142</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-428-02</org_study_id>
    <nct_id>NCT02846142</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers</brief_title>
  <official_title>A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteostasis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteostasis Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This trial will consist of three parts: the first two parts will enroll healthy female&#xD;
      volunteers into a single ascending dose (SAD) and multiple ascending dose (MAD) treatment&#xD;
      groups.&#xD;
&#xD;
      The SAD treatment group is comprised of at least 3 cohorts where subjects will be randomized&#xD;
      to a single dose of either PTI-428 or placebo and will be followed for 7 days post dose. A&#xD;
      total of 24 subjects are anticipated to participate in this part of the study.&#xD;
&#xD;
      Following the conclusion of the respective SAD level dose groups and after sufficient review&#xD;
      of study data and approval by the SRC, a second set of healthy adult female subjects will&#xD;
      participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3&#xD;
      cohorts where subjects will be randomized to either PTI-428 or placebo and will be followed&#xD;
      for a total of 14 days. The SRC will convene after the completion of each cohort to evaluate&#xD;
      safety, PK and other relevant data. The SRC will determine whether to proceed to the next&#xD;
      planned dose level, to reduce the dose, or to stop the study. The next cohort may commence&#xD;
      only after written SRC approval. A total of 24 subjects are anticipated to participate in&#xD;
      this part of the study.&#xD;
&#xD;
      Following completion of the SAD and MAD, 40 female healthy volunteers will participate in two&#xD;
      treatment periods of the DDI study component: Treatment period A will consist of once daily&#xD;
      oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).&#xD;
&#xD;
      Treatment period B will randomize subjects to PTI-428 or placebo in combination with once&#xD;
      daily OC for 28 days (21-day hormonal active and PTI-428 or placebo + 7 days off). Following&#xD;
      completion of the subjects' second treatment period, they will be followed for 7-days after&#xD;
      their last dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAD and MAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs</measure>
    <time_frame>baseline to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Apparent terminal half-life (t1/2) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Time to reach maximum plasma concentration (Tmax) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Maximum plasma concentration (Cmax) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Apparent terminal half-life (t1/2) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Time to reach maximum plasma concentration (Tmax) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Maximum plasma concentration (Cmax) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Cumulative amount of PTI-428 excreted unchanged in urine (Ae)</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: renal clearance (CLR)</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Cumulative amount of PTI-428 excreted unchanged in urine (Ae)</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: renal clearance (CLR)</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OC: Time to reach maximum plasma concentration (Tmax) of multiple oral doses</measure>
    <time_frame>through day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OC: Maximum plasma concentration (Cmax) of multiple oral doses</measure>
    <time_frame>through day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OC: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of multiple oral doses</measure>
    <time_frame>through day 49</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>SAD PTI-428</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD PTI-428</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI Period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI Period B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-428</intervention_name>
    <arm_group_label>MAD PTI-428</arm_group_label>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI Period B</arm_group_label>
    <arm_group_label>SAD PTI-428</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>MAD placebo</arm_group_label>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI</arm_group_label>
    <arm_group_label>SAD placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol and levonorgestrel</intervention_name>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI</arm_group_label>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI Period A</arm_group_label>
    <arm_group_label>OC (ethinyl estradiol and levonorgestrel) DDI Period B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult females age 18 - 55 years old, inclusive, at the time of informed consent.&#xD;
&#xD;
          -  For the DDI Oral Contraceptive Cohort, women of child bearing potential with intact&#xD;
             ovarian function by medical history and history of regular menstrual. cycles.&#xD;
&#xD;
          -  Body mass index (BMI) â‰¥18 &lt; 30 kg/m2.&#xD;
&#xD;
          -  Subject must be non-smoker and non-tobacco user for a minimum of 30 days prior to&#xD;
             screening and for the duration of the study.&#xD;
&#xD;
          -  Subject understands the full nature and purpose of the study, including possible risks&#xD;
             and side effects, and is willing and able to comply with all compulsory study&#xD;
             procedures and provides informed consent/permission prior to any study procedures&#xD;
             being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current evidence of any clinically significant cardiac, endocrinologic,&#xD;
             hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,&#xD;
             dermatologic, psychiatric, renal, or other major disease, as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Abnormal liver function as defined by:&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin &gt; 1.5 x&#xD;
             upper limit of the normal range.&#xD;
&#xD;
          -  Abnormal renal function at screening defined as:&#xD;
&#xD;
          -  Creatinine clearance &lt; 80mL/min using the Cockroft-Gault equation.&#xD;
&#xD;
          -  No clinically significant screening results that would exclude subject from the study&#xD;
             (e.g., medical histories, physical examination, ECGs, vital signs,and laboratory&#xD;
             profiles) as deemed by the investigator.&#xD;
&#xD;
          -  Platelet count &lt; 150,000 cell/mm3&#xD;
&#xD;
          -  Participation in another clinical trial or treatment with an investigational agent&#xD;
             within 30 days or 5 half-lives, whichever is longer, prior to Study Day 1.&#xD;
&#xD;
          -  History of cancer within the past five years (excluding non-melanoma skin cancer).&#xD;
&#xD;
          -  History of alcohol or drug abuse or dependence within 12 months of screening as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          -  Positive urine screen for prohibited drugs (cocaine, cannabinoids, nicotine [urine&#xD;
             cotinine is the detection mechanism for nicotine], opiates, barbiturates,&#xD;
             amphetamines, and benzodiazepines) or positive alcohol test at screening.&#xD;
&#xD;
          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C virus antibody (HCVAb).&#xD;
&#xD;
          -  Clinically significant infection within 3 months of screening as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Known or suspected hypersensitivity or idiosyncratic reaction to study medication or&#xD;
             any components thereof.&#xD;
&#xD;
          -  Has donated blood within 3 months of screening or plans to donate blood within 3&#xD;
             months of study completion.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Any conditions that, in the opinion of the Investigator, would make the subject&#xD;
             unsuitable for enrollment or could interfere with the subject's participation in or&#xD;
             completion of the study.&#xD;
&#xD;
          -  Females of child-bearing potential, unless they are willing to use highly effective&#xD;
             methods of contraception during participation in the clinical study and for 30 days&#xD;
             after termination from study.&#xD;
&#xD;
          -  Use of prohibited medications within 14 days prior to dosing of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

